Lung Transplant
Conditions
Keywords
Lung Transplant; Transplantation lung
Brief summary
The XVIVO Registry is to collect standard of care clinical data from "all-comers" who are transplanted with an EVLP lung treated with the XVIVO Perfusion System™ in order to assess the long-term performance of the device, and monitor device-related serious adverse events. In addition, 4 and 5-year UNOS registry data of the 126 subjects who received an EVLP transplant under the NOVEL and NOVEL Extension studies are provided as part of the long-term safety and quality of life data. In addition, 4 and 5-year UNOS registry data of the 126 subjects who received an EVLP transplant under the NOVEL and NOVEL Extension studies are provided as part of the long-term safety and quality of life data.
Detailed description
The XVIVO registry is an ongoing, observational, multicenter, retrospective review of patients exposed to XPS™ EVLP-treated lungs. The Registry study is aligned and managed by the UNOS and OPTN data collection process. This registry uses quarterly STAR file data requests for the OPTN data managed by UNOS. The EVLP procedure and transplantation will be performed per XPS™ Instructions for Use and the treating physician's discretion. Post-transplant clinical care will follow the institution's standard-of-care policies. OPTN updated the data collected since the submission of the protocol therefore the data collection has changed. The following data has updated collection: * Collects if hospitalized since last follow-up (yes, no), not the number of hospitalizations * Collects acute rejection episodes (yes treated, yes not treated, no), not the number of episodes * Collects Karnofsky Score as replacement for Physical and functional capacity * Employment limitations has been updated to working for income (yes or no) * No longer collects BOS, XVIVO to request BOS evaluations on subjects with visits prior to June 30, 2020 and any other omissions of end points not available in the data requested via STAR request. * Collects FEV1 (L) effective June 30, 2020 to calculate CLAD and diagnosis of CLAD, if applicable. * No longer provides Other, Specify text in STAR request.
Interventions
DEVICEXVIVO Perfusion System (XPS™) with STEEN Solution™
XVIVO Perfusion System (XPS™) with STEEN Solution™
Sponsors
XVIVO Perfusion
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
This is an "All Comers Registry" hence will include all patients receiving EVLP lungs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Survival at 1 year post-transplant | 12 months | Primary effectiveness endpoint |
| Primary Graft Dysfunction (PGD) | 72 hours | Rate of Grade 3 Primary Graft Dysfunction (PGD) at 72 hours |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Post-transplant survival | 2 years, 3 years, 4 years and 5 years post-transplant | Survival at 2, 3, 4 and 5 years post-transplant |
| Pulmonary Function Test (FEV1) | 1 year, 2 years, 3 years, 4 years and 5 years post-transplant | Pulmonary Function Test (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEV1 is the key lung function test in diagnosing BOS. FEV1 test at 1 year, 2 years, 3 years, 4 years and 5 years post-transplant. |
| Incidence of Bronchiolitis Obliterans Syndrome (BOS) or Chronic Lung Allograft Dysfunction (CLAD) | 1 year, 2 years, 3 years, 4 years and 5 years post-transplant | Rate of Grade 0 through 3 Bronchiolitis Obliterans Syndrome (BOS) at 1 year, 2 years, 3 years, 4 years and 5 years post-transplant. Clinically, BOS is associated with a progressive decline in forced expiratory volume in one second (FEV1) greater than or equal to 20% of baseline. Decline in FEV1 % increases the risk of development of BOS (Grade 0 to 3). CLAD is defined as a substantial and persistent decline (≥ 20%) in measured FEV1 value from the reference (baseline) value after lung transplantation, with or without a change in FVC. If CLAD is identified, staging and phenotype will be assigned. |
| Hospitalizations | 1 year, 2 years, 3 years, 4 years and 5 years post-transplant | The presence of in-patient hospital admissions between transplant and 1 year, 1-2 years, 2-3 years, 3-4 years, and 4-5 years post-transplant |
| Acute Rejection Episodes | 1 year, 1-2 years, 2-3 years, 3-4 years, and 4-5 years post-transplant | The presence of biopsy proven hospital admissions between transplant and 1 year, 1-2 years, 2-3 years, 3-4 years, and 4-5 years post-transplant |
| Karnofsky Performance Status Scale (KPS)/Karnofsky score | 1 year, 2 years, 3 years, 4 years and 5 years post-transplant | Karnofsky Performance Status Scale is an assessment tool for functional impairment. It is used to improve understanding of patient needs, ability to carry out daily activities and to assess patient prognosis. Karnofsky score is calculated at 1 year, 2 years, 3 years, 4 years and 5 years post-transplant. Higher the Karnofsky score, better the ability to carry out daily activities. |
| Safety Endpoint | 30 days post-transplant | XPS related SAEs from transplant to 30 days post-transplant or initial hospital stay, whichever is longer |
Countries
United States
Contacts
STUDY_DIRECTORSarah Lowe
XVIVO Perfusion
Outcome results
None listed